The main development of the Novosibirsk startup is a special inhaler for patients with tuberculosis and oncological diseases, which differs from its analogues by lower toxicity and better absorption. Special mention should be made of the fingerprint scanner and work with cloud platforms on Android and iOS operating systems.
It all works in the following way: a cartridge containing the necessary preparation is inserted into the aerosol inhaler. Then a person puts his or her finger to the device and the system automatically determines who is going to use the device now and what dose of medicine is needed for that particular person. But that's not all: as soon as the patient takes the medicine, the data will be immediately transferred to the client's mobile application, and the attending physician will be able to see it thanks to the cloud. This way, he or she will be able to control the treatment.
The company's main goal is to reduce the number of side effects of chemotherapy treatment. At the moment, the digital inhaler project has already attracted considerable investments of 305 million rubles from the Russian Venture Company. It is expected that the product will appear in the Russian market this year and will cost from five to twenty thousand rubles for personal use. And by 2025, according to the authors, at least one third of all specialized state medical institutions will have it in their everyday use.
RVC Fund has invested 305 million rubles in the development of digital PM&HM inhalers.
Internet Initiative Development Fund (IIDF) invested 195 million rubles in PM&HM
By 2025, the company plans to equip at least 30% of all specialized state medical institutions.